Breakthrough Pain Clinical Trial
Official title:
Quality of Life Study in Patients With Breakthrough Cancer Pain Treated in Medical Oncology Services
In cancer patients, pain is one of the most common symptoms. The range of reported prevalence of pain varies from 33% to 64% including different stages of cancer, during or after anticancer treatment. Moreover, despite the optimal management of basal chronic pain, 66% of these patients have reported breakthrough pain which has a severe impact on quality of life. There is insufficient clinical information on the quality of life of cancer patients with breakthrough pain treated in medical oncology services according to routine clinical practice. For this reason we consider it is appropriate to prospectively evaluate the quality of life of cancer patients with cancer breakthrough pain in medical oncology services as well as other factors that can affect quality of life. This post-authorization observational study will assess the quality of life of cancer patients with breakthrough cancer pain treated in medical oncology services in Spanish hospitals.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00994760 -
Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years
|
N/A | |
| Completed |
NCT01842893 -
Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer
|
Phase 3 | |
| Completed |
NCT02886286 -
Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain
|
Phase 4 | |
| Completed |
NCT02869321 -
Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy
|
Phase 4 | |
| Completed |
NCT02840500 -
Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units
|
N/A | |
| Completed |
NCT02437929 -
Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment
|
N/A | |
| Completed |
NCT00236145 -
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
|
Phase 3 | |
| Completed |
NCT02836379 -
Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent
|
N/A | |
| Active, not recruiting |
NCT02278601 -
Comparison of Regimens MPIB, CIPCEA, PCEA
|
Phase 3 | |
| Terminated |
NCT00842829 -
Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
|
Phase 4 | |
| Recruiting |
NCT05200806 -
A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy
|
Phase 4 | |
| Withdrawn |
NCT03809455 -
Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients
|
Phase 2 | |
| Completed |
NCT02050503 -
Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis
|
N/A | |
| Terminated |
NCT00387010 -
Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain
|
Phase 3 | |
| Withdrawn |
NCT05053308 -
Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement
|
N/A | |
| Recruiting |
NCT04011150 -
Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour
|
Phase 3 | |
| Terminated |
NCT01901718 -
An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray.
|
N/A | |
| Completed |
NCT00402350 -
Staccato Fentanyl Single and Multidose PK
|
Phase 1 | |
| Completed |
NCT00236041 -
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
|
Phase 2 |